Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
Clinical trial NCT04889118 · COMPLETED
Trial details
- NCT number
- NCT04889118
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-14
- Primary completion
- 2023-01-18
- Enrollment
- 131
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.